Close Menu

research and development

The researchers are developing an automated machine-learning approach to analyze the expression of protein markers associated with cervical cancer.

The additional €5 million from the European Investment Bank will co-fund R&D across the platforms and product portfolios of Curetis and Ares Genetics.

A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.

The developer said that use of gold nanoparticles enables use at the point of care and inexpensive signal amplification that eliminates traditional equipment.

The startup is developing a qPCR-based profiling method that could provide results within hours to clinicians treating their cancer patients with immune checkpoint inhibitors.

The group believes its assay, which detects HPV-16 DNA, could be deployed as a screening test in the way that HPV is currently screened to prevent cervical cancer.

The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.

The firm withdrew its 2020 revenue guidance and missed Wall Street estimates for both revenues and earnings.

The firms have already completed proof-of-concept studies for their semiconductor biosensor chips and Roswell plans to have the initial chips by 2021.

Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.

Pages